Ghazal Tansir | Oncology | Best Researcher Award

Published on 15/09/2025 by Global Academic Awards

Dr. Ghazal Tansir | Oncology | Best Researcher Award

All India Institute Of Medical Sciences Delhi | India

Dr. Ghazal Tansir, is an accomplished medical oncologist and researcher with a distinguished academic and clinical trajectory, holding an MBBS from Vardhman Mahavir Medical College, an MD in Internal Medicine from PGIMER, and a DM in Medical Oncology from AIIMS, New Delhi. She has served as Senior Resident and Research Consultant at AIIMS and is currently Assistant Professor at CAPFIMS-AIIMS, New Delhi. Dr. Tansir is an active member of the American Society of Clinical Oncology, European Society of Medical Oncology, and Indian Society of Medical and Pediatric Oncology. She has received multiple honors, including gold medals in Community Medicine and Ophthalmology, the AK Gadpayle Gold Medal in MD, selection for the ACORD protocol development workshop, the ASCO Merit Award, the ESMO Travel Grant, and the IDEA Award by Conquer Cancer. Her research contributions encompass over fifteen publications, focusing on rare cancers, sarcomas, and translational oncology, with studies on synovial sarcoma, mesenchymal chondrosarcoma, desmoid tumors, Li Fraumeni syndrome, and young-onset lung cancer. Dr. Ghazal Tansir has presented her work extensively at international conferences, including ASCO, ESMO, and the Connective Tissue Oncology Society, earning recognition for clinical and translational research excellence, making her a highly impactful researcher in medical oncology.

Profile: Google Scholar

Featured Publications

Tansir, G., Gupta, C., Mehta, S., Kumar, P., Soneja, M., & Biswas, A. (2017). Expanded dengue syndrome in secondary dengue infection: A case of biopsy proven rhabdomyolysis induced acute kidney injury with intracranial and intraorbital bleeds. Intractable & Rare Diseases Research, 6(4), 314–318.

Kumar, P., Tansir, G., Sasmal, G., Dixit, J., & Sahoo, R. (2016). Left pulmonary agenesis with right lung bronchiectasis in an adult. Journal of Clinical and Diagnostic Research: JCDR, 10(9), OD15.

Tansir, G., Kumar, P., Pius, A., Sunny, S. K., & Soneja, M. (2019). Pseudo-pseudo Meigs’ syndrome: A rare presentation of systemic lupus erythematosus. Reumatismo, 71(2), 108–112.

Biswas, S., Kumar, P., Tansir, G., & Biswas, A. (2019). Case report: Cardiac tamponade in dengue hemorrhagic fever: An unusual manifestation of a common disease. The American Journal of Tropical Medicine and Hygiene, 101(2), 448.

Tansir, G., Rastogi, N., Ramteke, P., Kumar, P., Soneja, M., Biswas, A., Kumar, S., & Jorwal, P. (2017). Disseminated mucormycosis: A sinister cause of neutropenic fever syndrome. Intractable & Rare Diseases Research, 6(4), 310–313.

Portia Nkhumbuleni Ramashia | Radiation Oncology | Best Researcher Award

Published on 03/04/202503/04/2025 by Global Academic Awards

Ms. Portia Nkhumbuleni Ramashia | Radiation Oncology | Best Researcher Award

Ms. Portia Nkhumbuleni Ramashia, University of Johannesburg, South Africa

Ms. Portia Nkhumbuleni Ramashia is an experienced Radiation Therapist and academic, currently serving as a Radiotherapy Lecturer at the University of Johannesburg (UJ). With extensive experience in both public and private healthcare sectors, she is known for her leadership, analytical thinking, and ability to mentor colleagues in delivering high-quality oncology care. As a Research Ethics Committee Member and Departmental Research Committee Chairperson, she plays a key role in ensuring research integrity and policy adherence. Passionate about healthcare innovation and education, she supervises master’s students and actively contributes to global oncology research. 🌍📚

Publication Profile

Orcid

🎓 Education

Ms. Ramashia holds a Master of Technology in Radiography (2017), B-Tech in Radiation Therapy (2009), and a National Diploma in Radiation Therapy (2006) from the University of Johannesburg. She is currently pursuing a PhD in Public Health at UJ, focusing on healthcare access, quality, and cancer treatment advancements. Her academic journey reflects a strong commitment to radiotherapy excellence and public health research. 🎓🔬

💼 Experience

With over a decade of experience, Ms. Ramashia has excelled as a Radiation Therapy Lecturer at UJ since 2018, developing innovative teaching methodologies and supervising master’s students. She chairs research committees, ensuring compliance with faculty policies, and engages in multidisciplinary collaborations. As a Radiation Therapist, she has worked in both public and private healthcare, pioneering strategies to enhance radiotherapy access and quality. She frequently presents her research at global conferences, influencing radiotherapy practices worldwide. 🏥📖

🏆 Awards & Honors

Ms. Ramashia has been recognized for her academic and research contributions, securing the NRF Black Academic Advancement Program (BAAP) Grant (2024) and being invited to the 2024 NRF Next Generation and Emerging Researchers Symposium. She has also been selected to attend the prestigious 16th HOPE Meeting with Nobel Laureates (2025). Her achievements highlight her impact on oncology research and academic excellence. 🏅🔬

🔬 Research Focus

Her research interests span cancer treatment effectiveness, healthcare disparities, health economics, global health, and quality improvement in radiotherapy. She explores barriers to radiotherapy access in Sub-Saharan Africa, evaluates novel radiotherapy planning tools, and investigates strategies for enhancing survivorship care. Her work contributes to policy development and innovative solutions in oncology. 🌍🩺

Publication Top Notes

📌 Improving Access to Radiotherapy Services in Gauteng: Quantitative Analysis of Key Time Intervals from Diagnosis to Treatment (2025) – International Journal of Environmental Research and Public Health 🔬📊 | DOI: 10.3390/ijerph22040544

📌 Barriers to Radiotherapy Access in Sub-Saharan Africa for Patients with Cancer: A Systematic Review (2024) – International Journal of Environmental Research and Public Health 🌍🏥 | DOI: 10.3390/ijerph21121597

📌 Radiography Managers’ Perceptions on Skills Required in Public Health Institutes in Gauteng (2024) – Health SA Gesondheid 🏥📑 | DOI: 10.4102/hsag.v29i0.2654

📌 Radiotherapy Plan Evaluation Tool in a Resource-Limited Setting: Comparison of VERT and Treatment Planning Software (2023) – Journal of Medical Imaging and Radiation Sciences ⚡📊 | DOI: 10.1016/j.jmir.2023.07.014

📌 The Experiences of Mine Workers with Cancer (2018) – Health SA Gesondheid ⛏️🎗️ | DOI: 10.4102/hsag.v23i0.1176

Conclusion

Ms. Portia Nkhumbuleni Ramashia’s contributions to radiotherapy research, cancer care disparities, and healthcare quality improvement position her as a strong candidate for the Research for Best Researcher Award. Her extensive publication record, academic leadership, research ethics involvement, and international recognition affirm her commitment to impactful and transformative research.

Tianzhu Qiu | Oncology | Women Researcher Award

Published on 03/04/202503/04/2025 by Global Academic Awards

Prof. Dr. Tianzhu Qiu | Oncology | Women Researcher Award

Prof. Dr. Tianzhu Qiu, the First Affiliated Hospital with Nanjing Medical University, China

Prof. Dr. Tianzhu Qiu is an esteemed oncology expert with a Ph.D. in Medicine from Nanjing Medical University. She serves as an Associate Chief Physician at Jiangsu Provincial People’s Hospital, specializing in colorectal cancer and immunotherapy. With a strong background in tumor microenvironment studies, mitochondrial autophagy, and immune mechanisms, she has led multiple clinical and translational research projects. She is actively involved in academic leadership, holding key positions in the Chinese Medical Doctor Association and the Chinese Anti-Cancer Association. As a prolific researcher, she has published over 10 SCI-indexed papers, contributed to national guidelines, and received numerous accolades, including the Jiangsu Medical Science and Technology Awards. Dr. Qiu is also a patent holder and a Deputy Editor of medical guidelines, showcasing her contributions to oncology research and healthcare innovation.

Publication Profile

Scopus

Education 🎓

Prof. Dr. Tianzhu Qiu earned her Ph.D. in Medicine from Nanjing Medical University, a leading institution known for its advanced medical research and education. Her academic journey was focused on oncology, particularly exploring colorectal cancer, immunotherapy, and tumor microenvironment mechanisms. During her doctoral studies, she gained expertise in single-cell transcriptomics, proteomics analysis, and high-dimensional immunofluorescence techniques, which have significantly contributed to her research. She further specialized in mitochondrial autophagy and immune response mechanisms, refining her technical skills in bioinformatics and molecular biology. Her Ph.D. research laid the foundation for her later work in translational oncology, where she has made significant breakthroughs in understanding cancer progression and treatment. Through continuous learning and collaboration with global experts, she has positioned herself as a leading figure in oncology research, contributing to both academic and clinical advancements in cancer treatment.

Experience 🏥

Dr. Tianzhu Qiu has extensive experience in oncology, serving as an Associate Chief Physician at Jiangsu Provincial People’s Hospital. She has led clinical and translational research, focusing on colorectal cancer, immunotherapy, and tumor microenvironment studies. Her work involves conducting advanced studies on mitochondrial autophagy and immune mechanisms, aiming to enhance treatment effectiveness and patient outcomes. She has played a key role in multiple national and provincial research projects, acting as Principal Investigator and Co-Investigator. Additionally, she has actively contributed to medical academia, serving as Secretary & Member of the Immunotherapy Committee of Colorectal Cancer and holding leadership positions in oncology-related committees. Her research has been instrumental in developing innovative cancer treatment strategies, and she has contributed to national medical guidelines. Through her experience, Dr. Qiu continues to bridge the gap between fundamental cancer research and clinical application, improving therapies and patient care.

Awards & Honors 🏆

Dr. Tianzhu Qiu has been recognized for her outstanding contributions to oncology with prestigious awards. She has received the First Prize and Second Prize in the Jiangsu Medical Science and Technology Awards for her innovative research in colorectal cancer and immunotherapy. These honors highlight her pioneering work in tumor microenvironment studies, mitochondrial autophagy, and immune response mechanisms. Her groundbreaking research has also earned her multiple research grants and leadership positions in oncology-related committees. As an esteemed researcher, she has been invited to present her work at top conferences, including ASCO-GI and ICIMH. Additionally, she has been granted eight patents for her innovative cancer treatment methodologies. Her contributions to oncology are further acknowledged through her role as Deputy Editor of the CACA Exercise Rehabilitation Guidelines. These accolades solidify her reputation as a leading oncology researcher, continuously advancing cancer treatment strategies.

Research Focus 🔬

Dr. Tianzhu Qiu’s research is centered on colorectal cancer, immunotherapy, and tumor microenvironment dynamics. She has made significant contributions to understanding mitochondrial autophagy and its role in cancer progression. Her work also involves single-cell transcriptomics and proteomics analysis, helping to uncover novel biomarkers and therapeutic targets. Utilizing advanced techniques such as multiplex immunofluorescence and high-dimensional bioinformatics, she has developed new approaches for cancer diagnosis and treatment. Her research extends into humanized mouse models to study tumor behavior and immune response in real-time. As Principal Investigator and Co-Investigator in multiple national and provincial projects, she has contributed to major advancements in cancer therapy. Her work has been widely published, with over 400 citations in SCI-indexed journals. By bridging molecular research with clinical applications, she continues to drive innovations in precision oncology and immunotherapy, improving outcomes for cancer patients worldwide.

Publication Top Notes

1️⃣ Evaluating AI in medicine: a comparative analysis of expert and ChatGPT responses to colorectal cancer questions – Scientific Reports, 2024 📆 | Cited by: 10 📑

2️⃣ Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): An open-label, single-arm, phase 2 trial – Journal for ImmunoTherapy of Cancer, 2023 📆 | Cited by: 42 📑

Conclusion

Prof. Dr. Tianzhu Qiu is a highly accomplished researcher in oncology, with significant contributions to colorectal cancer treatment, immunotherapy, and tumor microenvironment studies. Her leadership roles, strong publication record, research innovations, and national recognition make her an outstanding candidate for the Research for Women Researcher Award.

Sharada Mokkapati | Cancer Biology | Best Researcher Award

Published on 20/01/202520/01/2025 by Global Academic Awards

Dr. Sharada Mokkapati | Cancer Biology | Best Researcher Award

Dr. Sharada Mokkapati, The UT MD Anderson Cancer Center, United States

Dr. Sharada Mokkapati is an Assistant Professor of Urology (Research) at UT MD Anderson Cancer Center, specializing in oncology, molecular biology, and gene therapy. With a PhD in Genetics from the University of Cologne, Germany (2007), Dr. Mokkapati has contributed significantly to bladder cancer research. She was a key team member in the first FDA-approved gene therapy for bladder cancer and has extensive experience with gene therapy vector development, RNA/DNA molecular techniques, and NextGen sequencing. Her research also includes the identification of miRNA biomarkers and the study of tumor metabolism in gene therapy responses. Dr. Mokkapati has received multiple awards, including the Dodie P. Hawn Fellowship and the Lennox K. Black International prize for excellence in medicine. She is also an adhoc reviewer for journals like BMC Cancer and has co-authored numerous influential publications on bladder cancer and cancer therapy.

Publication Profile

Scopus

Education

Dr. Sharada Mokkapati earned her PhD in Genetics from the University of Cologne, Germany, in February 2007. Her academic journey has focused on genetic research, exploring complex biological systems to understand various genetic disorders. With a robust foundation in genetic principles, she has contributed significantly to the scientific community through research, publications, and collaborations. Dr. Mokkapati’s work has emphasized advancing knowledge in molecular genetics, genetic markers, and hereditary diseases, making a lasting impact on the field. Her dedication continues to inspire the next generation of genetic researchers. 🌱📚

Professional Experience 🌟

Dr. Sharada Mokkapati has an extensive career in academia and research. Since 2020, she has served as an Assistant Professor in Urology (Research) at the UT MD Anderson Cancer Center. Previously, she was an Instructor in Urology (Research) at the same institution from 2015 to 2020. Dr. Mokkapati’s academic journey began with a postdoctoral fellowship in the Department of Genetics at UT MD Anderson Cancer Center (2008-2015). Her early career includes graduate studies in Dermatology at the University of Cologne (2002-2007), and research roles at SPIC Science Foundation and Malladi Drugs & Pharmaceuticals in India. 🧬🔬

Research Achievements 🧬🔬

Dr. Sharada Mokkapati has made significant contributions to the field of oncology and gene therapy. She was a key team member in the development of the first FDA-approved gene therapy for bladder cancer. With extensive experience in oncology, molecular biology, biochemistry, biotechnology, and biomedical research, Dr. Mokkapati has developed and validated vectors for gene therapy. She is highly proficient in RNA, DNA, protein molecular techniques, biochemical assays, and NextGen sequencing. Additionally, Dr. Mokkapati excels in using both xenograft and genetically engineered mouse models for translational biology studies and managing research-related compliance and clinical trial databases. 🧪💡

Awards and Honors 🏅🎓

Dr. Sharada Mokkapati has been recognized with several prestigious awards throughout her career. She was honored with the “Dodie P. Hawn Fellowship in Genetics” at UT MD Anderson Cancer Center. Dr. Mokkapati also received the “Travel Award-Lennox K. Black International Prize for Excellence in Medicine” for her contribution to the 12th International Symposium on Basement Membranes in Philadelphia. As a team member, she contributed to the technology transfer for amylase and tannase at SPIC Science Foundation, India. Additionally, she qualified the “National Eligibility Test for Lectureship (NET)” and received the “Dr. T. Ramachandra Rao Memorial Gold Medal” for academic excellence in her Master’s studies. 🏆🧬

Research Focus 🔬💡

Dr. Sharada Mokkapati’s research primarily focuses on oncology, molecular biology, and gene therapy in the context of bladder cancer. She has contributed extensively to the molecular profiling of bladder cancer, identifying relevant subtypes for biomarker discovery. Her work also includes the development and validation of gene therapy vectors, particularly in non-muscle invasive bladder cancer. Dr. Mokkapati is proficient in RNA/DNA/protein molecular techniques, biochemical analysis, and NextGen sequencing, using mouse models to address both basic biological and translational studies. Her efforts aim to integrate gene therapies into bladder cancer treatment paradigms. 🧬🧫🎯

Publication Top Notes

Molecular profiling of bladder cancer xenografts defines relevant molecular subtypes and provides a resource for biomarker discovery (2025) – Cited by 0 🔬📚
Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer (2025) – Cited by 0 🧬💡
Concomitant antihistamine administration improves survival outcomes in urothelial carcinoma treated with atezolizumab (2025) – Cited by 0 💊📈
Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon α gene therapy in a murine bladder cancer model (2024) – Cited by 0 🧪🧬
Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval (2023) – Cited by 7 🏥🔬
The current status of gene therapy in bladder cancer (2023) – Cited by 8 📖🔍
Lentiviral interferon: A novel method for gene therapy in bladder cancer (2022) – Cited by 8 🧬🧪
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer (2022) – Cited by 16 🧪🔬
TCF21 promotes luminal-like differentiation and suppresses metastasis in bladder cancer (2020) – Cited by 7 🧬💥
Generation of a novel mouse strain with conditional, cell-type specific, expression of DND1 (2019) – Cited by 2 🐁🔬

Roger KoggeEnang | Soil Science | Best Researcher Award

Published on 30/07/202403/08/2024 by Global Academic Awards

Dr. Roger Kogge Enang | Soil Science | Best Researcher Award

Dr. Gabriel Espinosa Carrasco, University of Dschang, Cameroon

Dr. Roger Kogge Enang is a strong candidate for the Best Researcher Award due to his extensive background and contributions in soil science and environmental research. Here’s why he stands out:

Publication profile

Orcid

Extensive Research Output:

Since 2016, Dr. Enang has been actively publishing, with at least two scientific articles per year. His research spans various critical areas in soil science, including soil classification, nutrient cycling, and pollution remediation.

Educational Background:

He holds a Ph.D. and MSc in Soil Science, and a BSc in Chemistry, with a specialization in environmental chemistry and soil fertility. His academic credentials underpin his solid research foundation.

Diverse Research Interests:

His research covers vital topics such as soil mineralogy, soil organic matter, and digital soil mapping. He has contributed significantly to understanding soil properties and their implications for agriculture and environmental management.

Professional Involvement:

Dr. Enang is an active member of several professional organizations, including the Cameroon Soil Science Society and the International Network on Soil Pollution. His roles in these organizations reflect his commitment to advancing the field.

Field and Laboratory Experience:

His practical experience includes extensive soil surveys, experimental design, and advanced laboratory analyses. This hands-on expertise enhances the applicability and impact of his research findings.

Notable Publications:

Dr. Enang has published numerous peer-reviewed articles in reputable journals, demonstrating his ability to contribute valuable knowledge to the scientific community.

Given his track record of impactful research, extensive publications, and professional dedication, Dr. Roger Kogge Enang is highly suitable for the Best Researcher Award.

Gabriel Espinosa Carrasco | Cancer Immunology | Best Researcher Award

Published on 26/07/202429/07/2024 by Global Academic Awards

Dr. Gabriel Espinosa Carrasco | Cancer Immunology | Best Researcher Award

Postdoctoral fellow Memorial Sloan Kettering Cancer Center Spain

Gabriel Espinosa Carrasco, Ph.D., is a seasoned immunologist renowned for his research on T cell dysfunction and immunotherapy. With a robust background in biological sciences and immunology, he has contributed significantly to understanding how different immune cell populations interact to combat cancer and autoimmune diseases. His career is marked by his leadership abilities and a strong network of collaborators in the immunology field.

Profile

Scopus

Education 🎓

Dr. Espinosa Carrasco holds a Ph.D. in Biological Sciences and Immunology from the University of Montpellier (2011-2016). He earned his Master’s in Advanced Immunology from the University of Barcelona in 2011 and a Bachelor’s degree in Biology from the Autonomous University of Barcelona in 2010.

Experience 🧑‍🔬

Currently, Dr. Espinosa Carrasco is a Post-doctoral Scholar at the Cancer Virotherapy and Immunotherapy Group at Bellvitge Institute for Biomedical Research (IDIBELL). He previously held a postdoctoral position at Memorial Sloan-Kettering Cancer Center, where he worked on projects related to intratumoral immune triads. His Ph.D. research at INSERM Unit 1183 focused on T cell interactions in autoimmune diabetes.

Research Interests 🔬

Dr. Espinosa Carrasco’s research interests lie in the development of new immunotherapies for solid tumors. He focuses on strategies to reverse T cell dysfunction, particularly the role of CD4 and CD8 T cells in tumor immunity. His work includes studying immune cell triads to enhance antitumor responses.

Awards 🏆

Dr. Espinosa Carrasco has received numerous accolades, including the 2024 Best Researcher Award (provisionally), a grant from the Ludwig Center for Basic and Translational Immunology, and the Third Prize Poster Presentation Award at the Tumor Microenvironments Symposium in 2019. He was also an invited seminar speaker at Georgetown University in 2017.

Publications Top Notes📚

Gabriel Espinosa-Carrasco et al. “Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors.” Cancer Cell, 2024. 10.1016/j.ccell.2024.05.025 (Cited by 25 articles).

Mojdeh Shakiba, Gabriel Espinosa-Carrasco et al. “TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion.” J Exp Med, 2022. 10.1084/jem.20201966 (Cited by 40 articles).

Sofia V. Gearty, Gabriel Espinosa-Carrasco et al. “An autoimmune stem-like CD8 T cell population drives type 1 diabetes.” Nature, 2022. 10.1038/s41586-021-04155-4 (Cited by 50 articles).

Gabriel Espinosa-Carrasco et al. “Integrin beta 1 optimizes diabetogenic T cell migration and function in the pancreas.” Frontiers in Immunology, 2018. 10.3389/fimmu.2018.01156 (Cited by 30 articles).

Gabriel Espinosa-Carrasco et al. “CD4+ T helper cells play a key role in maintaining diabetogenic CD8+ T cell function in the pancreas.” Frontiers in Immunology, 2018. 10.3389/fimmu.2018.02001 (Cited by 35 articles).

Ken Kato | Oncology Award | Excellence in Research

Published on 18/06/202418/06/2024 by Global Academic Awards

Dr. Ken Kato | Oncology Award | Excellence in Research

Dr. Ken Kato, National Cancer Center Hospital, Japan

Dr. Ken Kato is a distinguished Japanese oncologist specializing in gastrointestinal and esophageal cancers. With a robust career at the National Cancer Center Hospital in Tokyo, he leads divisions in translational research and medical oncology 🏥. Holding both an M.D. and a Ph.D. from prestigious institutions 🎓, Dr. Kato has a notable presence in clinical and research domains, with expertise in molecular targets and immunotherapy for cancer 🧬. His extensive publications in top medical journals highlight his dedication to advancing cancer treatment 📚. Dr. Kato is also an active member of several professional societies worldwide 🌏.

Publication profile

Scopus

Education

Dr. Kato earned his Ph.D. from Kyushu University in 2001 and his M.D. in 1995. He graduated from the University of Occupational and Environmental Health in 1989 🎓.

Research Focus

Dr. Ken Kato is a leading researcher in gastrointestinal and esophageal cancers, focusing primarily on early detection, treatment, and the molecular mechanisms of these malignancies 🧬. His work includes innovative studies on serum microRNAs for early gastric cancer detection, biomarkers for chemotherapy response, and the genetic underpinnings of cancer resistance 📊. He has explored the efficacy of various chemotherapeutic combinations, such as S-1 plus cisplatin for HER2-positive gastric cancer, and has investigated the impact of gene mutations in treatment outcomes 🚑. Dr. Kato’s research aims to advance precision medicine in oncology, improving patient survival and treatment efficacy 🌟.

Publication Top Notes

A novel combination of serum microRNAs for the detection of early gastric cancer – Abe, S., Matsuzaki, J., Sudo, K., … Saito, Y., Ochiya, T. Gastroenterological Endoscopy, 2021, 63(6), pp. 1310 📅, Cited by: 0 🔍
ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy – Takahashi, T., Yamahsita, S., Matsuda, Y., … Nagino, M., Ushijima, T. Journal of Cancer Research and Clinical Oncology, 2015, 141(3), pp. 453–463 📅, Cited by: 21 📊
Efficacy of S-1 plus cisplatin combination chemotherapy in patients with HER2-positive advanced gastric cancer – Honma, Y., Shimada, Y., Takashima, A., … Sekine, S., Kushima, R. International Journal of Clinical Oncology, 2014, 19(5), pp. 863–870 📅, Cited by: 3 📈
Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer – Takahashi, N., Yamada, Y., Taniguchi, H., … Hamaguchi, T., Shimada, Y. BMC Research Notes, 2014, 7(1), 271 📅, Cited by: 41 🔬
Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection – Shoji, H., Yamada, Y., Taniguchi, H., … Hamaguchi, T., Shimada, Y. Cancer Science, 2014, 105(8), pp. 1002–1007 📅, Cited by: 24 🧬
Combined Assessment of Endothelial Growth Factor Receptor Dual Color In Situ Hybridization and Immunohistochemistry with Downstream Gene Mutations in Prediction of Response to the Anti-EGFR Therapy for Patients with Metastatic Colorectal Cancer – Takahashi, N., Yamada, Y., Taniguchi, H., … Hamaguchi, T., Shimada, Y. Archives of Medical Research, 2014, 45(5), pp. 366–374 📅, Cited by: 7 🔍
A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI) – Kato, K., Muro, K., Ando, N., … Nagai, K., Kato, H. Esophagus, 2014, 11(3), pp. 183–188 📅, Cited by: 30 🩺
Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: Combined analysis of the Japan Clinical Oncology Group Trials JCOG9205 and JCOG9912 – Takashima, A., Boku, N., Kato, K., … Shimada, Y., Ohtsu, A. Gastric Cancer, 2014, 17(3), pp. 522–528 📅, Cited by: 26 📊
Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma – Hayashi, H., Arao, T., Matsumoto, K., … Nishio, K., Yamada, Y. Oncotarget, 2014, 5(9), pp. 2588–2595 📅, Cited by: 33 🧪
Feasibility of endoscopic mucosal resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage IB, II, and III esophageal squamous cell cancer – Makazu, M., Kato, K., Takisawa, H., … Yamada, Y., Shimada, Y. Diseases of the Esophagus, 2014, 27(1), pp. 42–49 📅, Cited by: 31 🩹